Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Eupraxia Pharmaceuticals ( (TSE:EPRX) ).
On March 17, 2026, Eupraxia Pharmaceuticals reported new six‑month symptom data from the highest dose cohort in the Phase 1b/2a portion of its RESOLVE trial of EP‑104GI in eosinophilic esophagitis, showing a mean 4‑point reduction in Straumann Dysphagia Index scores in the top-dose cohort where 3 points defines clinical remission. Across mid‑to‑high dose cohorts, clinical remission rates reached 59% at 12 weeks and 76% at 24 weeks, with improvements strengthening over time, underscoring the potential value of continuous local steroid delivery in this chronic inflammatory disease.
An added 6 mg/site cohort using larger 19‑gauge catheters restored dose‑response relationships and delivered markedly better histologic and symptom outcomes than an earlier 6 mg/site group, highlighting the importance of device choice for drug delivery. Safety data remain strong, with 31 patients and more than 220 patient‑months of follow‑up showing no serious adverse events, no oropharyngeal candidiasis, and good tolerability up to the highest 8 mg/site dose, while a placebo‑controlled Phase 2b segment of RESOLVE is now recruiting 120 mg and 160 mg regimens with top‑line results expected in the third quarter of 2026, a catalyst that could be pivotal for the program’s and company’s clinical and commercial trajectory.
The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$11.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.
Spark’s Take on EPRX Stock
According to Spark, TipRanks’ AI Analyst, EPRX is a Neutral.
The score is held back primarily by the pre-revenue model with widening losses and rising cash burn, despite a notably improved, low-debt balance sheet. Technical indicators also reflect weak near-term momentum, and valuation signals are limited by negative earnings and lack of dividend support.
To see Spark’s full report on EPRX stock, click here.
More about Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing locally delivered, extended-release therapies for conditions with significant unmet medical need, using its proprietary Diffusphere polymer-based microsphere drug-delivery technology. Its pipeline includes EP-104GI for inflammatory gastrointestinal disease such as eosinophilic esophagitis and EP-104IAR for knee osteoarthritis pain, with potential expansion into oncology, infectious disease and other inflammatory joint indications.
The company focuses on optimizing targeted, long-acting delivery of existing and novel drugs to specific tissues, aiming to improve efficacy and safety by minimizing systemic exposure. Eupraxia is listed on Nasdaq and the Toronto Stock Exchange under the ticker EPRX and operates from Victoria, British Columbia, serving global markets where chronic inflammatory and pain conditions remain poorly controlled by current therapies.
Average Trading Volume: 93,444
Technical Sentiment Signal: Buy
Current Market Cap: C$628.7M
Learn more about EPRX stock on TipRanks’ Stock Analysis page.